Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.
| Revenue (Most Recent Fiscal Year) | $6.94M |
| Net Income (Most Recent Fiscal Year) | $-212.39M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5593.85% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -50.56% |
| Return on Assets (Trailing 12 Months) | -46.93% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.08 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.08 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.75 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.65 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.43 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 113.58M |
| Free Float | 105.39M |
| Market Capitalization | $1.90B |
| Average Volume (Last 20 Days) | 1.50M |
| Beta (Past 60 Months) | 2.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.21% |
| Percentage Held By Institutions (Latest 13F Reports) | 44.58% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |